Featured Articles From The Current Issue
CELLULAR MICROENCAPSULATION - Cell Encapsulation for Drug Delivery & Disease Treatment
Gerald W. Crabtree, PhD, indicates drug or treatment delivery that employs microencapsulation, one of many promising developments in the field of regenerative medicine, offers not only treatments but also potential cures for a wide variety of maladies.

>>> See All Cover Stories

Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
Detlev Haack, PhD, and Martin Koeberle, PhD, believe one exciting alternative starting to gain traction in the industry is assessment via an electronic tongue to detect and analyze all the compounds responsible for taste within a sample.
Matthew Moorcroft, PhD, warns that in the fast-moving pharmaceutical industry, change is the only constant. And to keep up with market developments, small molecule manufacturers must first understand the trends.
Dawn A. Firmin, MSc, PhD, explains how MGB has dedicated its focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria.
Craig Morgan says as clinical trials continue to evolve, drug companies will no longer be able to rely on existing, tried-and-tested manual methods or point solutions for success. And technology integration in the eClinical stack is not sufficient to bring about the step change in productivity that has to happen.
Dr. Susanne Resatz, President of Vetter Development Services USA, Inc., discusses the many benefits to small biotech companies in utilizing the services of a full-service CDMO, and what advanced services the Chicago-based facility offers its growing customer base.
Ryan Littich, PhD, highlights some of the most significant, pathogen-borne diseases relevant to food-producing animals and reviews the antimicrobial properties intrinsic to midchain triglyceride lipolysis products.
Christi Bird indicates sample preparation remains a critical task in many research and testing workflows across biopharmaceutical, basic research, clinical, and industrial applications. While the market lacks the hype and excitement of NGS, CRISPR/Cas9, or the microRNA and epigenetics boom several years ago, the sample preparation market will always be a slow and steady gainer on an already large market size.
Jerzy Wojcik says it is more important than ever to bring the right team together early in a project to capture product requirements correctly. The cost of missing needs or requirements goes up exponentially as development proceeds, and many of these requirements can be identified early in the project if the right individuals are at the table.
Daniel C. Smith, PhD, indicates there remains a clear need for improved process productivities, and the need to develop manufacturing processes that can be applied to a wide number of AAV-based viral vector therapeutic candidates.
Kaiser J. Aziz, PhD, says the availability of validated biomarker-drug companion products will enable the molecular diagnostics and pharmaceutical industries to develop and rely on new genomic biomarkers in order to elucidate disease pathways, stratify patient populations, and monitor safe and effective use of these products.
Racheli Ofir, PhD, and Noa Sher, PhD, report on studies showing that PLX-R18 is a strong candidate for the treatment of H-ARS as well as a plethora of bone marrow failures with similar symptomatology.
Exclusive Online Content
SteadyMed Raises $30 MillionSteadyMed Raises $30 Million
SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has entered into a definitive agreement to sell its ordinary shares and warrants to purchase its ordinary shares for aggregate gross proceeds of approximately $30 million in a private placement.

Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science ProductsCrown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has launched an e-commerce platform to support the commercialization of its Life Science products.

Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian CancerPipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer, according to research and consulting firm GlobalData.

New Glatt GPCG 10 Fluid Bed Granulator at MetricsNew Glatt GPCG 10 Fluid Bed Granulator at Metrics
Enhancing its known expertise in developing multi-particulate and modified-release drug products, Metrics Contract Services has acquired a new Glatt GPCG 10 fluid bed granulator with Wurster inserts.

Aptar Pharma Unveils its eDose Counter for MDIs at RDD Europe 2017Aptar Pharma Unveils its eDose Counter for MDIs at RDD Europe 2017
Aptar Pharma recently announced it will present its patented eDose Counter for Metered Dose Inhalers (MDIs) at the RDD Europe 2017 conference in Nice France, April 25-28, 2017.

Gattefossé Announces Inauguration of its North America Technical Center of ExcellenceGattefossé Announces Inauguration of its North America Technical Center of Excellence
To expand its presence in the North American region, the Gattefossé Group announces the establishment of its fourth Technical Center of Excellence, located in Paramus, New Jersey.

MedCision Announces the ThawSTAR Early Adopter Program for Limited TimeMedCision Announces the ThawSTAR Early Adopter Program for Limited Time
MedCision, a leader in the automation of basic clinical processes, recently announced the ThawSTAR Cell Thawing Early Adopter Program for companies undergoing early cell therapy trials.

HealthFactors Announces Collaboration With Koronis Biomedical TechnologiesHealthFactors Announces Collaboration With Koronis Biomedical Technologies
HealthFactors, Inc. and Koronis Biomedical Technologies (KBT) recently announced a formal collaboration designed to improve healthcare and outcomes for people with respiratory conditions associated with asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

Capsugel Expands Late-Stage Inhalation Product Development CapabilitiesCapsugel Expands Late-Stage Inhalation Product Development Capabilities
Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced the expansion of its late-stage inhalation capabilities to advance dry powder inhalation (DPI) concepts through late-stage clinical trial and commercial production.

Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First TimeAptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the US prescription market for the first time with Allergan’s RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) 0.05%.
Market News & Trends


Click here to see the showcases

RDD (Respiratory Drug Delivery)
April 25-28
Nice, France

Pre-filled Syringes East Coast
April 26-27
Boston, MA

AAPS National Biotechnology Meeting
May 1-3
San Diego, CA

Innovation Networking Summit & Table-top Exhibition
May 4-5
Hilton Hotel, Parsippany, NJ

CPhI North America & Informex
May 16-18
2017 Philadelphia, PA

Pre-filled Syringes West Coast
June 5th & 6th, San Diego, USA

BIO 2017

June 19 - 22
San Diego, CA

Controlled Release Society Meeting
July 16-19 Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Nienna, Austria

November 12-17
San Diego, CA


Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions